Recent Biotech Financings: Viamet, Intellikine, Xenoport, Zosano
This article was originally published in The Pink Sheet Daily
Executive Summary
At least for these four companies, there are no summer doldrums in investment activity; Viamet is a notable example of increased participation by big pharma venture groups in early-stage biotech financings.
You may also be interested in...
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
The news that FDA rejected GlaxoSmithKline/XenoPort's NDA for Horizant (gabapentin enacarbil) for restless leg syndrome due to a carcinogenicity signal in rats took Wall Street by surprise and crushed XenoPort, which lost more than half its market value Feb. 18. The companies issued a press release announcing receipt of an FDA "complete response" letter for Horizant after the market closed on Feb. 17